Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

EMUC 2024: Optimising strategies in mHSPC and mCRPC

Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz

EMUC 2024: Optimising strategies in mHSPC and mCRPC ( Prof Gerhardt Attard, Prof Wolfgang Fendler, Dr Lynda Corrigan, Prof Jochen Walz )

Debate: Challenges and solutions for new treatment options in mUC

Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr...

Debate: Challenges and solutions for new treatment options in mUC ( Dr. María José Juan Fita, Dr. Bernadett Szabados, Prof. Rafael S. Grajewski, Dr. Diego Teyssonneau )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

One-year mortality in older adults with breast cancer: prediction using...

Dr Tabassum Wadasadawala and Dr Shivani Sable

One-year mortality in older adults with breast cancer: prediction using different geriatric tools ( Dr Tabassum Wadasadawala and Dr Shivani Sable )

Isa-VRd shows greater efficacy compared to VRd in intransplant-ineligible NDMM...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Isa-VRd shows greater efficacy compared to VRd in intransplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Optimising benefit-risk and minimising impact on quality of life with BCMA...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Use of Bispecifics and CAR T cells in South America

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Use of Bispecifics and CAR T cells in South America ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

More from ecancer